{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:09:20Z","timestamp":1788232160974,"version":"build-2803163510"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clml.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T19:26:15Z","timestamp":1697916375000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies"],"prefix":"10.1016","volume":"24","author":[{"given":"Mark","family":"Forsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.006_bib0001","unstructured":"Howlader N NA, Krapcho M, Miller D, et\u00a0al.(eds) SEER Cancer Statistics Review, 1975-2017. National Cancer Institute. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2017\/[Last accessed on July 27, 2023]."},{"key":"10.1016\/j.clml.2023.10.006_sbref0002","series-title":"Chronic lymphocytic leukemia. [Updated 2023 Jan 15]. In: StatPearls [Internet]","author":"Mukkamalla","year":"2023"},{"key":"10.1016\/j.clml.2023.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0005","unstructured":"\"Center for Drug Evaluation and Research - Application 208573Orig1s000 - Division Director Summary Review\" (PDF). U.S. Food and Drug Administration (FDA). 2016."},{"key":"10.1016\/j.clml.2023.10.006_bib0006","unstructured":"FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. U.S. Food and Drug Administration (FDA) (Press release). 2016. Retrieved 25 April 2020. Public Domain This article incorporates text from this source, which is in the public domain."},{"key":"10.1016\/j.clml.2023.10.006_bib0007","unstructured":"FDA approves venetoclax for CLL or SLL, with or without 17p deletion, after one prior therapy. U.S. Food and Drug Administration (FDA) (Press release). 8 June 2018. Retrieved 25 April 2020. Public Domain This article incorporates text from this source, which is in the public domain."},{"key":"10.1016\/j.clml.2023.10.006_bib0008","unstructured":"FDA approves venetoclax in combination for AML in adults. U.S. Food and Drug Administration (FDA). 21 November 2018. Retrieved 25 April 2020. Public Domain This article incorporates text from this source, which is in the public domain."},{"issue":"30","key":"10.1016\/j.clml.2023.10.006_bib0009","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in elderly acute myeloid leukemia trial(CAVEAT): a phase Ib dose-escalation study of Venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.10.006_bib0010","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.10.006_bib0011","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3\u00a0+\u00a07 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2023.10.006_bib0012","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2023.10.006_bib0013","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.006_bib0014","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.clml.2023.10.006_bib0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.10.006_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.10.006_bib0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2023.10.006_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibs.2013.12.006","article-title":"Many players in BCL-2 family affairs","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem Sci"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0019","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2019.09.008","article-title":"Venetoclax in lymphoid malignancies: new insights more to learn","volume":"36","author":"Thijssen","year":"2019","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.clml.2023.10.006_bib0020","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1042\/BCJ20170080","article-title":"Therapeutics targeting Bcl-2 in hematological malignancies","volume":"474","author":"Ruefli-Brasse","year":"2017","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.clml.2023.10.006_bib0021","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0022","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/sj.leu.2400854","article-title":"High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.006_bib0031","article-title":"Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia","volume":"13","author":"VJ","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0023","doi-asserted-by":"crossref","first-page":"e1721","DOI":"10.1038\/cddis.2015.97","article-title":"BCL-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2023.10.006_bib0024","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0026","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t (11,14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2023.10.006_bib0027","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0028","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.clml.2023.10.006_bib0029","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2023.10.006_bib0030","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0032","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00262-021-03043-x","article-title":"Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype","volume":"71","author":"Elias","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2023.10.006_bib0033","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.10.006_bib0034","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2023.10.006_bib0035","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0036","unstructured":"Beat Acute Myeloid Leukemia (AML) 1.0 was accessed on July 27 July, 2023 from https:\/\/registry.opendata.aws\/beataml."},{"key":"10.1016\/j.clml.2023.10.006_bib0037","doi-asserted-by":"crossref","unstructured":"Shanshan Pei, Austin E Gillen, Ian T Shelton, et\u00a0al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. bioRxiv. 2022. doi:10.1101\/2022.12.04.519036","DOI":"10.1101\/2022.12.04.519036"},{"issue":"13","key":"10.1016\/j.clml.2023.10.006_bib0038","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0039","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2019-128499","article-title":"NOTCH2 contributes to venetoclax resistance in chronic lymphocytic leukemia","volume":"134","author":"Fiorcari","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0040","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0041","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.clml.2023.10.006_bib0042","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1535-7163.MCT-21-0690","article-title":"Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells","volume":"21","author":"Carter","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.clml.2023.10.006_bib0043","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40364-021-00288-7","article-title":"Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0044","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0045","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12935-020-01614-z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clml.2023.10.006_bib0046","first-page":"1195","article-title":"The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5\u2032 and 3\u2032 ends of genes","volume":"130","author":"Sampathi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0047","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","article-title":"ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment","volume":"17","author":"Patel","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0048","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"5","key":"10.1016\/j.clml.2023.10.006_bib0050","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","article-title":"Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-Cell lymphoma","volume":"22","author":"Klanova","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0051","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.2147\/DDDT.S194787","article-title":"Salvianolic acid A attenuates CCl4-induced liver fibrosis by regulating the PI3K\/AKT\/mTOR, Bcl-2\/Bax and caspase-3\/cleaved caspase-3 signaling pathways","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.clml.2023.10.006_bib0052","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive b-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0053","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2023.10.006_bib0054","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/19336918.2017.1393591","article-title":"Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion","volume":"12","author":"Young","year":"2018","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.clml.2023.10.006_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696532","article-title":"FOXM1-AKT positive regulation loop provides venetoclax resistance in AML","volume":"11","author":"Chesnokov","year":"2021","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.10.006_bib0057","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.10.006_bib0059","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0058","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142655","article-title":"Activation of the ERK pathway drives acquired resistance to venetoclax in MM cell models","volume":"136","author":"Chakraborty","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0060","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-19-2339","article-title":"Improving response to FLT3 inhibitors\u2013BCL2 the rescue?","volume":"25","author":"Perl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0061","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0062","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0063","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","article-title":"IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line","volume":"18","author":"Dumon","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2023.10.006_bib0064","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","article-title":"FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation","volume":"114","author":"Yoshimoto","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0065","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/ijms24043161","article-title":"Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (NPM1) Mutation","volume":"24","author":"Chin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.clml.2023.10.006_bib0066","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML: rationale and clinical evidence","volume":"9","author":"Darici","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0067","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0068","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.10.006_bib0069","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/cdd.2015.74","article-title":"MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors","volume":"22","author":"Knorr","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2023.10.006_bib0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2023.10.006_bib0071","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0072","doi-asserted-by":"crossref","unstructured":"Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) Onco Targets Ther. 2019;12:2903-10. doi:10.2147\/OTT.S172315.","DOI":"10.2147\/OTT.S172315"},{"issue":"12","key":"10.1016\/j.clml.2023.10.006_bib0073","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0074","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"issue":"35","key":"10.1016\/j.clml.2023.10.006_bib0076","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.10.006_bib0077","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2022-157210","article-title":"Updated results from a phase I\/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia","volume":"140","author":"Short","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107313","article-title":"Alternating venetoclax\/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia","volume":"130","author":"Oya","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0079","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0080","doi-asserted-by":"crossref","unstructured":"Kadia TM, Borthakur G, Pemmaraju N, et\u00a0al. Phase II study of venetoclax added to cladribine\u00a0+\u00a0low dose AraC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia (AML) Blood. 2020;136:17-9. doi: 10.1182\/blood-2020-142092.","DOI":"10.1182\/blood-2020-142092"},{"key":"10.1016\/j.clml.2023.10.006_bib0081","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.18632\/oncotarget.2175","article-title":"Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2023.10.006_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.777587","article-title":"Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia b cells by inducing mcl-1","volume":"11","author":"Fiorcari","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0083","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","article-title":"Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax","volume":"5","author":"Lachowiez","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.10.006_bib0084","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2023.10.006_bib0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.clml.2023.10.006_bib0086","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.10.006_bib0087","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired Mutations in Bcl2 family proteins conferring resistance to the Bh3 mimetic Abt-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.10.006_bib0088","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.3390\/ijms24065802","article-title":"Landscape of BCL2 resistance mutations in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukemia treated with venetoclax","volume":"24","author":"Kotmayer","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clml.2023.10.006_bib0089","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2021013788","article-title":"A BAX door to venetoclax resistance","volume":"139","author":"Izzo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.10.006_bib0091","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0092","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0093","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.10.006_bib0094","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41418-023-01117-0","article-title":"Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs","volume":"30","author":"Diepstraten","year":"2023","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.clml.2023.10.006_bib0095","first-page":"1","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.clml.2023.10.006_bib0096","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2023.10.006_bib0097","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2023.10.006_bib0098","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0099","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0100","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.10.006_bib0101","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.10.006_bib0102","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.10.006_bib0103","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0104","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2019-126790","article-title":"Combined EZH2 and BCL2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"134","author":"Gibbs","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.10.006_bib0105","doi-asserted-by":"crossref","first-page":"7798","DOI":"10.1182\/blood-2022-166997","article-title":"Discovery of HZ-L105, a next generation of Bcl-2 Inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.10.006_bib0106","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.10.006_bib0107","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2019-129783","article-title":"First-in-human study of Abbv-621, a TRAIL receptor agonist fusion protein, in patients (Pts) with relapsed\/refractory (RR) acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL)","volume":"134","author":"Jonge","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0108","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.006_bib0109","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/cancers15030745","article-title":"DRP1 Inhibition Enhances venetoclax-induced mitochondrial apoptosis in TP53-mutated acute myeloid leukemia cells through BAX\/BAK activation","volume":"15","author":"Jang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2023.10.006_bib0110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ijms18010144","article-title":"Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals","volume":"18","author":"Hu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2023.10.006_bib0111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0112","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.clml.2023.10.006_bib0113","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0114","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.626117","article-title":"Mitochondrial OMA1 and OPA1 as gatekeepers of organellar Structure\/Function and cellular stress response","volume":"9","author":"Gilkerson","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.clml.2023.10.006_bib0116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nm.4232","article-title":"Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth","volume":"23","author":"Cramer","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0117","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.clml.2023.10.006_bib0118","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.10.006_bib0119","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2023.10.006_bib0120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2019-131336","article-title":"MCL-1 and PKA\/AMPK axis fuel venetoclax resistance in lymphoid cancers","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0121","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions","volume":"10","author":"Samra","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.10.006_bib0122","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/antiox11030461","article-title":"Venetoclax-resistant MV4-11 leukemic cells activate PI3K\/AKT pathway for metabolic reprogramming and redox adaptation for survival","volume":"11","author":"Alkhatabi","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.clml.2023.10.006_bib0123","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2023.10.006_bib0124","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.clml.2023.10.006_bib0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.10.006_bib0126","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0127","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1200\/JCO.2022.40.16_suppl.7018","article-title":"A phase Ib\/II study of ivosidenib with venetoclax +\/- azacitidine in IDH1-mutated hematologic malignancies","volume":"40","author":"Lachowiez","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clml.2023.10.006_bib0128","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.10.006_bib0129","doi-asserted-by":"crossref","first-page":"20931","DOI":"10.18632\/aging.104207","article-title":"OPA1, a new mitochondrial target in cancer therapy","volume":"12","author":"Herkenne","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.clml.2023.10.006_bib0130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2023.10.006_bib0131","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.2021012623","article-title":"Evading eviction: leukemic stem cell squatters","volume":"138","author":"Krause","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.10.006_bib0132","first-page":"302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2023.10.006_bib0133","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.006_bib0134","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2020006343","article-title":"CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues","volume":"138","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.006_bib0135","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.006_bib0136","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0137","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 \u2009+ \u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.10.006_bib0138","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 axis in tumor immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clml.2023.10.006_bib0139","article-title":"Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia","volume":"13","author":"Martinez","year":"2023","journal-title":"Front Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:20Z","timestamp":1761871400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502302150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S215226502302150X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}